HIV Drug Therapy: Lower-dose Efavirenz Equally Effective with Fewer Side Effects

A reduced dose of efavirenz (Sustiva or Stocrin) for first-line HIV therapy suppressed viral load as well as the standard dose, but was associated with fewer characteristic side effects, researchers reported at the recent HIV Drug Therapy 2014 meeting in Glasgow. A related study found that half the dose maintained viral suppression in people with high efavirenz levels in their blood.

Read more:

HIV Drug Therapy: Darunavir/Ritonavir Protease Inhibitor Monotherapy Less Effective than 3-Drug ART

Monotherapy with ritonavir-boosted darunavir (Prezista) results in a lower rate of viral suppression after 48 weeks when compared to darunavir/ritonavir plus 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), but may be just as effective as 3-drug therapy in people with nadir (lowest-ever) CD4 cell counts above 200 cells/mm³, according to a 48-week analysis of the PROTEA study presented last week at the HIV Drug Therapy Glasgow conference.

Read more:

HIV Drug Therapy: Efavirenz Not Linked to Higher Suicide Risk in D:A:D Cohort

People taking antiretroviral therapy (ART) regimens containing the NNRTI efavirenz (Sustiva) were not more likely to die due to suicide or psychiatric illness than those taking other drugs in the large D:A:D cohort, researchers reported last month at the HIV Drug Therapy 2014 meeting in Glasgow.

Read more:

HIV Drug Therapy: Doravirine Works as Well as Efavirenz with Fewer CNS Side Effects

Once-daily doravirine (MK-1439), an experimental NNRTI, demonstrated viral suppression similar to that of efavirenz at 48 weeks, and the dose selected for further development was associated with fewer central nervous system (CNS) side effects, researchers reported this week at the International Congress on Drug Therapy in HIV Infection in Glasgow.

Read more:

Complete Coverage of HIV Drug Therapy 2014

HIVandHepatitis.com coverage of the HIV Drug Therapy 2014 Conference Research, November 2-6, 2014, in Glasgow, Scotland.

Full listing of coverage by topic

HIV Drug Therapy 2014 website

11/4/14

HIV Drug Therapy: Truvada PrEP Use Rising, Especially Among Men

The number of people using Truvada for pre-exposure prophylaxis (PrEP) in the U.S. is increasing, and a growing proportion of users are men, according to an analysis of data from approximately half of American pharmacies presented this week at the HIV Drug Therapy 2014 conference in Glasgow.

Read more:

HIV Drug Therapy: Once-daily Dolutegravir Superior to Darunavir at 96 Weeks

Treatment with a triple antiretroviral combination containing the once-daily integrase inhibitor dolutegravir (Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir (Prezista) over 96 weeks of follow-up, Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported this month at the HIV Drug Therapy Glasgow conference.

Read more:

HIV Drug Therapy: Australia Performs Best in HIV Treatment Cascade -- 62% Undetectable Viral Load

Australia and northern European countries are doing far better than North America at retaining people living with HIV in care and achieving viral suppression, according to a comprehensive survey of treatment cascades in high-income countries presented this week at the International Congress on Drug Therapy in HIV Infection in Glasgow.

Read more: